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INTRODUCTION
Breast cancer remains the most common cancer in
women and the second leading cause of cancer deaths in
women [1]. Although patients with limited-stage disease are
often cured with standard multimodality therapy, the prog-
nosis for patients with multinode-positive disease remains
poor. There are considerable data demonstrating the corre-
lation between survival after the diagnosis of breast cancer
and the number of lymph nodes involved at the time of
surgery. Although adjuvant chemotherapy has improved the
outcome in many patients, those with extensive lymph node
involvement continue to suffer high mortality rates. In
women with primary breast cancer involving 10 or more
lymph nodes, 55% to 87% will relapse within 5 years [2-4].
Results for patients with 4 to 9 positive lymph nodes are also
disappointing, with ≥50% of patients treated with standard-
dose regimens relapsing by 5 years [5-9].
High-dose chemotherapy (HDC) with autologous
hematopoietic cell rescue has the advantage of a steep
therapeutic dose-response curve, characteristic of many
chemotherapeutic agents, without the disadvantage of
significant hematopoietic toxicity at higher doses. Initial
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ABSTRACT
Despite modern chemotherapy, advanced breast cancer remains a significant cause of cancer morbidity and mortal-
ity in women. Patients with disease involvement of multiple lymph nodes represent a subgroup with a high risk of
relapse. In particular, 50% of patients with 4 to 9 axillary lymph nodes involved will relapse after standard chemo-
therapy. In an effort to improve the survival of patients with 4 to 9 involved nodes, we performed a phase II study in
which 61 patients with surgically diagnosed stage II or III breast cancer and 4 to 9 positive lymph nodes received
3 cycles of doxorubicin and 5-fluorouracil followed by high-dose chemotherapy consisting of cisplatin, cyclophos-
phamide, and carmustine and infusion of autologous hematopoietic progenitor cells. All patients received posttrans-
plantation localized radiotherapy unless contraindicated, and all patients with hormone receptor–positive disease
received tamoxifen. After a median patient follow-up of 6.7 years (range, 4.6-8.6 years), the 5-year overall survival
rate was 79% (95% CI, 69%-90%), with relapse-free survival of 73% (95% CI, 62%-85%). Treatment-related mor-
tality was 3%. Interstitial pneumonitis occurred in 69% of patients but did not contribute to mortality. Our study
presents long-term favorable results regarding the use of consolidative HDC with autologous hematopoietic sup-
port in previously untreated patients with high-risk primary breast cancer.
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phase II trials conducted in the 1980s demonstrated that the
response rates in patients with metastatic breast cancer who
received combination HDC, with median survival durations
of 4.2 to 6.8 months, were superior to those in patients who
received standard-dose combination therapy. In particular,
with more than 13 years of follow-up, combination chemo-
therapy with cyclophosphamide, cisplatin, and carmustine
(CPB) yielded a response rate of 65% and progression-free
survival rate of 14% [10,11]. Although HDC results in high
response rates, responses appear durable predominantly in
those patients who are able to achieve a complete response
following HDC [12-14]. Therefore, incorporation of induc-
tion chemotherapy and consolidative hormonal and radio-
therapy has been used in later trials in an attempt to increase
the number of complete responders.
The Duke University Bone Marrow Transplant Program
previously performed a series of studies employing CPB in
the treatment of metastatic or locally-regionally recurrent
breast cancer. These studies demonstrated complete
response rates of 50% and long-term disease-free survival
(DFS) rates that showed signiﬁcant improvement compared
to those obtained with conventional-dose therapy [10,15,16].
After these encouraging results were obtained, a pilot study
was conducted in which patients with high-risk primary
breast cancer with 10 or more positive lymph nodes were
treated with intensive induction chemotherapy followed by
CPB and autologous hematopoietic support. With a median
follow-up of 6.5 years, according to comparison with histori-
cal controls, event-free survival (EFS) rates in these patients
were almost twice those in patients who received the same or
similar induction chemotherapy without CPB and autolo-
gous hematopoietic support [17]. The preliminary results of
a phase III randomized study in women with 10 or more pos-
itive lymph nodes comparing the results of treatment with
intermediate versus high-dose CPB showed no difference in
overall survival (OS) [18]. Disease-speciﬁc survival rates were
modestly improved with HDC, but the beneﬁt was offset by
treatment-related mortality. Longer follow-up is needed to
better assess the utility of HDC in these patients. Conclu-
sions drawn from these data are premature, as demonstrated
by the Dutch study [19] that showed, after an adequate follow-
up period, that treatment with HDC was beneﬁcial in the
initial subset of 284 patients. Because treatment with stan-
dard therapy has been shown to result in similar survival
rates for patients with 4 to 9 and patients with 10 or more
involved axillary lymph nodes, a comparable approach of
intensive induction chemotherapy followed by HDC and
autologous hematopoietic cell rescue was undertaken in
patients with 4 to 9 positive axillary nodes.
MATERIALS AND METHODS
Patient Selection
From August 1992 to February 1996, 72 women with
newly diagnosed stage II or III breast cancer and 4 to
9 involved axillary lymph nodes were referred to the Bone
Marrow Transplant Program at Duke University. After the
initial evaluation, each patient’s case was presented at a
weekly conference at which patients were reviewed for suit-
ability for enrollment. Eligibility criteria included patient
age ≥18 years, Karnofsky performance status of ≥80%, con-
ﬁrmation of all pathologic specimens and disease staging at
the transplantation center, and insurance approval. Patients
could not have received adjuvant chemotherapy. Eleven
patients were excluded for the following reasons: bone mar-
row involvement (n = 1), presence of inflammatory breast
cancer (n = 2), prior therapy (n = 3), previous breast cancer
(n = 3), and patient refusal to participate in study (n = 2).
Eligibility Criteria Prior to HDC
The following test results were mandatory for patients
undergoing registration and initiation of HDC and were
obtained within 4 weeks prior to enrollment: bilateral bone
marrow biopsies with ≥20% cellularity without evidence of
tumor involvement; hemoglobin [Hb] ≥10 g/dL; platelet
count ≥100,000/µL; absolute neutrophil count (ANC)
≥1800/µL; serum creatinine ≤1.8 mg/dL; blood urea nitrogen
≤1.5 × normal; estimated creatinine clearance ≥60 mL/min;
aspartate aminotransferase and bilirubin ≤2.5 × normal; neg-
ative β–human chorionic gonadotropin, human immuno-
deficiency virus antibody, and hepatitis B surface antigen;
computed tomographic (CT) scans of the head, chest, abdo-
men, and pelvis and bone scan without evidence of metasta-
tic disease; multiple-gated acquisition scan with ejection
fraction ≥45% at rest; and pulmonary function tests with cor-
rected carbon monoxide diffusing capacity (DLCO), 1-second
forced expiratory volume (FEV1), and forced vital capacity
(FVC) all ≥60%. All 61 patients proceeded to HDC.
Treatment Plan
All patients had previously undergone primary surgery
consisting of axillary lymph node dissection in addition to one
of the following procedures: radical mastectomy, modified
radical mastectomy, or lumpectomy. A minimum number of
sampled axillary nodes was not required for any of the
patients. Adjuvant chemotherapy included 3 cycles of doxoru-
bicin (80 mg/m2) and 5-ﬂuorouracil (AF) (800 mg/m2) given
as intravenous (IV) boluses every 14 days with granulocyte
colony-stimulating factor (G-CSF) support on days 3 through
10. Initiation of adjuvant chemotherapy had to occur within
8 weeks of the last breast cancer–related surgery.
Within 3 weeks of the last dose of AF chemotherapy
and subsequent hematopoietic recovery, the patients under-
went a bone marrow harvest as previously described [20]. A
minimum nucleated cell count of 1 × 108/kg was collected.
Cells were cryopreserved with dimethyl sulfoxide (DMSO)
and maintained in liquid nitrogen.
Peripheral blood progenitor cells (PBPCs) were mobi-
lized with subcutaneous daily injections of G-CSF 5 µg/kg
per day for a total of 5 consecutive days. Patients underwent
leukapheresis as previously described [21] on days 4 through
6 of G-CSF priming, and all patients met the goal of >1 ×
1010/kg nucleated cells or 2 × 106/kg CD34+ cells. PBPCs
were cryopreserved in liquid nitrogen with 10% DMSO.
After a minimum of 5 days from the last dose of G-CSF,
the following HDC regimen was initiated: cyclophosphamide
(CPA) 1875 mg/m2 per day IV over 1 hour on days –6 to –4
and concurrent cisplatin (cDDP) 55 mg/m2 per day via con-
tinuous IV infusion on days –6 to –4, followed by the imme-
diate administration of carmustine (BCNU) 600 mg/m2 IV
over 2 hours on day –3. All chemotherapy doses were calcu-
lated based on actual body weight (ABW) unless the patient’s
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body weight was >20% more than ideal body weight (IBW),
in which case the mean of the ABW and IBW was used. On
days –1 to +1, all patients received autologous PBPCs, which
were rapidly thawed at 37°C and infused over several minutes
via a large-bore central venous catheter. With a similar proce-
dure, bone marrow was rapidly thawed and reinfused on day
+1, approximately 3 hours after the last infusion of PBPCs.
Supportive Care
All patients received daily subcutaneous injections or IV
infusions of G-CSF 5 µg/kg per day after PBPC reinfusion,
beginning on day –1 and continuing until day +21, unless
ANC was ≥2500/mL for 3 days or ≥10,000/mL for 1 day.
Beginning on day –2 and continuing until ANC was
>500/mL, all patients received prophylactic antibiotics con-
sisting of ciprofloxacin 500 mg orally every 8 hours and
rifampin 300 mg every 12 hours [22]. In patients who devel-
oped febrile neutropenia (temperature >38.2°C), oral antibi-
otics were discontinued and broad-spectrum IV antibiotics
were initiated, with modiﬁcation of therapy based on culture
results. Antifungal therapy was initiated if the fever persisted
for 5 days of treatment with broad-spectrum antibiotics.
Criteria for blood-product support included Hb <10 g/dL
or platelet count ≤25,000/mL. All patients received irradi-
ated and leukoreduced ﬁltered blood products.
Tamoxifen
Estrogen receptor (ER) and progesterone receptor (PR)
status were considered positive if ≥7 fm/mg protein was pres-
ent or immunohistochemical staining was positive. Women
whose disease was hormone-receptor positive were initiated
on tamoxifen therapy 10 mg orally twice a day beginning
6 weeks after HDC and continuing for 5 years. A total of
41 patients received tamoxifen. In addition to the 39 women
with known hormone-receptor–positive tumors, the 2 patients
with unknown ER and PR status also received tamoxifen.
Three patients received incomplete therapy because of
relapsed disease (n = 1) or prolonged pancytopenia (n = 2). In
addition, 2 patients had an interruption in hormonal therapy
because of refractory emesis.
Posttransplantation Irradiation
Patients underwent local/regional radiotherapy approxi-
mately 6 weeks following completion of HDC unless they
had continued transplantation-related toxicities including
significant pulmonary toxicity, white blood cell count
(WBC) <3000/mL, or platelet count <50,000/mL. Six
patients had a delay in therapy because of the development
of interstitial pneumonitis. Nine patients did not receive
radiotherapy because of prolonged interstitial pneumonitis
(n = 7), development of Guillain-Barre syndrome (n = 1), or
development of idiopathic thrombocytopenic purpura (n =
1). The remaining 52 patients were scheduled to receive
50.4 Gy irradiation to the chest wall or ipsilateral remaining
breast, internal mammary, and supraclavicular nodes via
cobalt 60 or higher energy tangential photons, with an addi-
tional 10 to 15 Gy to the tumor bed or mastectomy scar
region, all in 1.8- to 2.0-Gy daily fractions 5 days a week.
Treatment delays were allowed for acute skin desquamation,
acute pulmonary toxicity, WBC <1500/mL, or platelet
count <30,000/mL. Five patients had delays in receiving a
complete radiotherapy course because of interstitial pneu-
monitis (n = 4) or the development of hemolytic uremic syn-
drome (n = 1). An additional 3 patients received only partial
therapy because of recurrent interstitial pneumonitis, the
development of prolonged pancytopenia, or the develop-
ment of progressive disease. The radiation therapy may have
varied somewhat because patients were treated at multiple
sites and the radiation therapy records were not reviewed.
Follow-up
After HDC, patients were evaluated at the transplanta-
tion center at 6 weeks, 6 months, and 1 year and annually
thereafter. At all follow-up visits, a complete physical exami-
nation was performed and samples obtained and analyzed
for complete blood count with differential and complete
chemistry panel results. Screening CT scans of the chest
and abdomen and bone scans were obtained annually.
Interstitial Pneumonitis
Baseline results of pulmonary function tests (PFTs),
including FVC, FEV1, and DLCO, were obtained prior to
study registration and after standard-dose chemotherapy.
Follow-up PFTs were performed 6 weeks after hemato-
poietic cell transplantation. Additional PFTs were performed
if signs/symptoms of pulmonary toxicity developed. DLCO
was corrected for Hb using the formula (1.7 × Hb)/(10.2 +
Hb). FVC, FEV1, and DLCO were expressed as percentage
predicted for the corresponding age, sex, and height of the
patient. The following criteria were used in the diagnosis of
interstitial pneumonitis: (1) no evidence/suspicion for infec-
tious etiologies; (2) development of nonproductive cough
and dyspnea, with or without fever, occurring several weeks
to months following consolidative HDC, and a fall in DLCO
to <60% predicted; (3) decline in DLCO to <50% predicted,
with or without symptoms. Patients in whom interstitial
pneumonitis was diagnosed were treated with prednisone,
beginning at a dosage of 60 mg/day for 2 weeks. Although
the dosage for most patients was tapered over 8 weeks, the
duration of therapy was individually adjusted based on clinical
response. Patients treated with prednisone received concur-
rent pneumocystis prophylaxis with oral sulfamethoxasole-
trimethoprim or aerosolized pentamidine.
Statistical Methods
Cox proportional hazards univariate regression models
were used to identify predictors of OS, relapse-free survival
(RFS), and EFS. We estimated OS and EFS according to
the Kaplan-Meier product limit method. We calculated EFS
from time of transplantation to disease progression or death,
whichever occurred first. Patients who were alive without
progressive disease were censored at the date of last follow-
up visit. OS was calculated from time of transplantation to
death, and patients who were alive were censored at date of
last follow-up visit.
RESULTS
Patient Characteristics
Table 1 lists the characteristics of the 61 patients ana-
lyzed in this study. The median age was 44 years (range,
26-58 years), and the majority of patients had stage II breast
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cancer (45 of 61). Prior to chemotherapy, most patients
underwent a modiﬁed radical mastectomy with a median of
7 involved lymph nodes. Thirty-nine (64%) of patients had
a positive hormone-receptor status.
Survival Data 
Survival data are shown in Figures 1 and 2. The median
follow-up was 6.7 years (range, 4.6-8.6 years). At 3 years, the
OS and EFS rates were 87% (95% conﬁdence interval [CI],
79%-96%) and 74% (95% CI, 64%-86%), respectively. RFS
was 78% (95% CI, 69%-89%). At 5 years, the OS and EFS
rates were 79% (95% CI, 69%-90%) and 69% (95% CI,
58%-82%), respectively. At the time of analysis, a total of
16 patients had evidence of recurrent disease, with a median
time to relapse of 1.72 years (range, 0.36-3.98 years).
Although only 3 patients relapsed within the ﬁrst year after
transplantation, all 16 patients relapsed within 4 years. Five
of the patients who relapsed had not received radiation or
had experienced a delay in receiving radiation, and none of
these 5 relapsed locoregionally. Fifteen patients died because
of disease; 2 deaths were due to treatment-related toxicity,
and 1 was due to previously undisclosed alcoholic liver dis-
ease. The median time to death in this group of 16 patients
was 2.2 years from transplantation. In the entire group of
patients, the median survival was not reached.
Toxicity
Two patients (3%) suffered treatment-related mortality,
one of an air embolus that occurred during administration
of total parenteral nutrition after transplantation and one of
hepatosplenic candidiasis/sepsis. A non–treatment-related
death noted at day 592 was a result of previously undisclosed
alcoholic liver disease.
Interstitial pneumonitis was the most frequent reported
complication, affecting 42 patients (69%) with a median
decrease in DLCO of 44% from baseline. The median time to
development of pneumonitis was 45 days (range, 10-411 days),
with 41 patients diagnosed within the first 6 months. No
deaths could be attributed to the development of interstitial
pneumonitis. There were no cases of significant regimen-
related hepatotoxicity including veno-occlusive disease,
nephrotoxicity, central nervous system toxicity, cutaneous
changes, microangiopathic hemolytic anemia, or secondary
cancers, including myelodysplastic syndrome.
PROGNOSTIC FACTORS
The following variables were analyzed using a univariate
Cox proportional hazards regression model to predict RFS:
age, tumor size, number of positive lymph nodes, propor-
tion of positive nodes, type of surgery, use of consolidative
radiotherapy, ER status, PR status, tamoxifen therapy in
Table 1. Patient Characteristics
Age at diagnosis, median (range), y 44 (26-58)
Primary tumor size, median (range), cm 3 (1-16)
Time to transplantation from diagnosis, 132 (89-472)
median (range), d
Stage, n
II 45
III 16
Surgery, n
Mastectomy 2
Modified radical mastectomy 37
Bilateral mastectomy 4
Lumpectomy + axillary lymph node dissection 15
Other 2
Unknown 1
Lymph node involvement, n
4 9
5 5
6 15
7 7
8 16
9 9
Hormonal status, n
ER/PR+ 28
ER+ only 4
PR+ only 7
Negative 20
Unknown 2
Figure 1. Kaplan-Meier overall survival curve.
M. J. Stuart et al.
670
hormone positive or postmenopausal patients, or the
development of interstitial pneumonitis. Table 2 outlines
the variables and P values. The number of positive nodes,
proportion of positive nodes, and degree of radicalness of
surgery were of borderline significance. Additionally, uni-
variate analyses were performed to predict EFS and OS;
consolidative radiotherapy and more radical surgery pre-
dicted an improved OS. The HER-2/neu status of the pri-
mary tumors was not available.
DISCUSSION
The prognosis of patients with primary breast cancer is
inversely related to the number of lymph nodes involved.
Despite conventional chemotherapy, patients with 10 or
more lymph nodes involved at the time of surgery have
relapse rates of 55% to 87% at 5 years [5,7,8,23]. Analysis of
the results of treatment outcomes for patients with 4 to 9
positive lymph nodes are equally grim, with a 50% to 60%
relapse rate at 5 years, increasing to 70% to 80% by 10 years
[5,6,8,24]. In particular, standard-dose CMF (cyclophos-
phamide, methotrexate, and 5-fluorouracil) and CAF
(cyclophosphamide, doxorubicin and 5-fluorouracil), com-
monly used adjuvant treatments, have led to 5-year DFS
rates of only 35% and 54%, respectively [5,25,26].
Because of the poor prognosis of patients with advanced
disease, the possibility of improving survival using dose-
escalation therapy with non–cross-resistant agents has been
studied. Historical studies such as those from the Mayo
Clinic and MD Anderson Center (FAC trials) have exten-
sive follow-up on the cohort of patients who achieved
complete remissions after extended chemotherapy [27].
Compared to these trials, trials with HDC achieve 2 to
15 times the number of complete remissions. However,
inherent difﬁculties exist in the analysis of nonmatched his-
torical controls. More compelling are the results of the
Figure 2. Kaplan-Meier event-free survival curve.
Table 2. P Values of Univariate Analyses for Prediction of EFS and OS
Variable RFS EFS OS Comparison
Nodes .083 .36 .32 Continuous
Surgery .50 .57 .26 Bilateral, lumpectomy, modified radical mastectomy
Radical* .053 .067 .026 Radical surgery
IP .65 .54 .30 Interstitial pneumonitis (yes/no)
RT .47 .10 .038 Radiation therapy (yes/no)
Tam .94 .93 .94 Tamoxifen (yes/no)
Age .65 .55 .74 Age dichotomized at 45
Age .23 .31 .72 Continuous
Prop Nodes +† .08 .14 .19 Proportion of positive nodes
ER/PR status .75 .75 .95 Either positive versus both negative
ER status .92 .85 .92 + versus –
PR status .74 .72 .93 + versus –
Tumor size .75 .68 .69 Continuous
Tumor size .95 .70 .87 ≤2 cm versus >2 cm
*The more radical the surgery, the higher the group survival rates. Compares bilateral mastectomies or modiﬁed radical mastectomy versus
lumpectomy or simple mastectomy.
†Formula for the calculation is number of positive nodes divided by number of nodes examined.
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Cancer and Leukemia Group B (CALGB) 8541 trial, which
compared 3 doses and schedules of CAF adjuvant therapy
for stage II/III breast cancer. A signiﬁcant improvement in
OS and DFS was seen in the higher dose arms [5]. Dose
escalation of a single agent, as demonstrated in CALGB
9344, with dose escalation of doxorubicin of 60 mg/m2 to
90 mg/m2, or NSABP B25, with a dose escalation of
cyclophosphamide of 1200 mg/m2 to 2400 mg/m2, did not
result in a survival benefit [28,29]. However, in one trial,
the addition of a non–cross-reactive agent, such as pacli-
taxel, resulted in early improvement in DFS and OS in
patients with hormone-receptor–negative tumors [29].
Because of initially encouraging data on treatment of
metastatic disease, patients with high-risk primary breast
cancer have been treated with HDC. In a phase II trial, Peters
et al. used HDC and autologous hematopoietic cell rescue
as consolidation after 4 cycles of standard-dose CAF adjuvant
chemotherapy. All 85 patients received posttransplantation
radiotherapy, and patients with hormone-receptor–positive
disease received up to 5 years of tamoxifen therapy. With a
median follow-up of 6.5 years, patient EFS was 65% [17,30].
Other single-institution studies have reported similar
results, and the International Bone Marrow Transplant Reg-
istry demonstrated a 3-year EFS after HDC of 65% and
60% for stage II and III disease, respectively, in patients
with ≥4 positive nodes [14,31-34]. Several prospective ran-
domized multicenter trials that will attempt to better clarify
potential beneﬁt are currently underway or have completed
enrollment, but to date no results have been published that
focus on the 4-to-9–positive-node patient group.
Initial studies using HDC in patients with 4 to 9 involved
lymph nodes have shown promising results. In a phase II
multicenter trial, 43 patients with stage II or III breast cancer
with 4 to 9 involved lymph nodes received standard AFM
chemotherapy (adriamycin, 5-ﬂuorouracil, and methotrexate)
followed by HDC (cyclophosphamide, thiotepa, and carbo-
platin) and chemotherapy-mobilized autologous hemato-
poietic cell rescue. OS was 77% and DFS was 67% at a
median of 4 years [31]. Bearman et al. reported similar results,
with a DFS of 71% at 4 years, using high-dose cyclophos-
phamide, cisplatin, and BCNU [32]. In a comparable study,
Hudis et al. investigated the use of “dose-dense” adjuvant
chemotherapy in patients with 4 or more positive lymph
nodes. A sequential schedule was used to optimize time of
exposure of doxorubicin and cyclophosphamide, and the
5-year DFS for 73 patients was 51.7% [35].
In a study based on these encouraging results, we inves-
tigated the efficacy of CPB HDC in patients with 4 to
9 involved axillary lymph nodes. With 3-year OS and RFS
rates of 87% and 78%, respectively, our data demonstrate
further improvement over historical data and results similar
to those of the other phase II transplantation studies. This
improvement may be partially related to the decreased
transplantation-related mortality, which is considerably
lower than the 10% to 20% reported in previously pub-
lished trials. The median time to relapse was 1.76 years,
with most patients with relapsed disease dying at 3 to 4 years
posttransplantation. No correlation could be found regard-
ing delay in any therapy, including transplantation, radiation
therapy, or hormonal therapy. However, this conclusion is
based on a relatively small sample size. Insufficient data
were available to assess whether relapse correlated with
Her-2-neu positivity. The University of Colorado group has
shown decreased survival in Her-2-neu–positive patients fol-
lowing transplantation [36].
The incidence of pneumonitis resulting from the HDC
regimen was higher in our study than that in studies using
other HDC regimens, but was comparable to the incidence
in a smaller group of patients previously reported by us [37].
The incidence of pneumonitis in our current study was also
markedly similar to the incidence of pneumonitis (72%) seen
in 75 patients treated under the CALGB 9082 protocol
described below [38]. The mechanism by which these similar
regimens lead to a higher incidence of pneumonitis is
unclear, but may involve enhanced oxidative lung injury and
the development of a proinﬂammatory environment due to
the chemotherapeutic agents used [37,38]. Systemic steroid
use appears beneﬁcial in the treatment of interstitial pneu-
monitis, a result that led our group to complete a study that
demonstrates a possible beneﬁcial effect of high-dose inhaled
steroid prophylaxis against the development of interstitial
pneumonitis [39]. Despite the higher incidence of pneu-
monitis seen in our study, no deaths resulted from pneu-
monitis. Deaths were likely prevented by frequent follow-up
and rapid administration of steroid therapy upon diagnosis.
Large-scale randomized trials may provide further insight
into the use of HDC in high-risk breast cancer patients. In a
phase III randomized trial, CALGB 9082 patients with 10 or
more positive nodes received 4 cycles of CAF followed by ran-
domization to either intermediate-dose CPB or high-dose
CPB therapy and autologous hematopoietic cell rescue, fol-
lowed by consolidated radiotherapy and tamoxifen. At a
median follow-up of 5 years, no statistical difference in EFS
between the treatment groups was seen [18]. In the Scandina-
vian trial, 525 women with either high-risk or metastatic dis-
ease to the bone or bone marrow were randomized to receive
either 3 cycles of 5-ﬂourouracil, epirubicin, and cyclophos-
phamide (FEC) followed by HDC with cyclophosphamide,
thiotepa, and carboplatin (CTCb) with autologous hemato-
poietic cell rescue or 9 cycles of tailored FEC. The OS was
70% in both arms at a median of 2 years [40]. The intergroup
study led by the Southwest Oncology Group, 9623, compared
dose-dense anthracycline cyclophosphamide and paclitaxel
with 4 cycles of CAF followed by transplantation for patients
with 4 to 9 involved lymph nodes. The study is closed to
accrual and data should be forthcoming in the next 1 to 2 years.
With a short follow-up time, the available analyses of
these trials are premature, and the high up-front mortality
rate in the transplantation arms likely contributes to the lack
of difference in survival results between treatment groups.
After a longer time for analysis, results from a third large-
scale trial are now favoring HDC. In the Dutch study, the
ﬁrst 284 out of 885 enrolled patients with ≥4 positive axil-
lary lymph nodes received 3 cycles of adjuvant FEC and
surgery. The patients were randomized to receive a fourth
cycle of FEC followed by either radiation therapy and
tamoxifen or high-dose CTCb and autologous hematopoietic
cell rescue followed by radiation therapy and tamoxifen. At a
follow-up of 3 years, there was a 15% improvement in
progression-free survival favoring the HDC group (77%
in the high-dose group versus 62% in the conventional-dose
chemotherapy group; P = .009) [19]. It is important to note
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that the HDC was administered as bolus infusions in this
study and not continuous infusions as previously reported
for that regimen. The bolus infusions resulted in 7-fold
increased 4-hydroperoxycyclophosphamide (4HC) levels
compared to levels obtained with continuous infusions. We
have previously reported on the importance of drug levels
and survival [41].
Considerable controversy exists around the use of HDC
and autologous transplantation in breast cancer. Patients with
multinodal involvement represent a subgroup with a high risk
of relapse. Our study presents favorable results regarding
consolidative HDC with autologous hematopoietic rescue in
previously untreated patients with 4 to 9 involved lymph
nodes. Although single-institution studies provide important
information regarding feasibility issues, rigid multicenter ran-
domized trials are required to truly compare HDC to other
therapies. We hope such trials will provide necessary informa-
tion regarding the overall beneﬁt of HDC.
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